Open AccessN-Terminal Prosomatostatin as a Risk Marker for Cardiovascular Disease and Diabetes in a General Population
Author(s) -
Tore Hedbäck,
Peter Almgren,
Peter M. Nilsson,
Olle Melander
Publication year - 2016
Publication title -
the journal of clinical endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.206
H-Index - 353
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/jc.2016-1736
Subject(s) - medicine , hazard ratio , diabetes mellitus , population , proportional hazards model , endocrinology , confidence interval , coronary artery disease , type 2 diabetes , gastroenterology , environmental health
Somatostatin inhibits a range of hormones, including GH, insulin, and glucagon, but little is known about its role in the development of cardiometabolic disease.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom